



The Current State of Public Payer **Access** to CGTs in Canada

The first cell and gene therapy (CGT) entered the Canadian market in 2018, with an increasing number of new products available for the treatment of various disease since then. The figures on the following page outline current publicly-funded CGTs, as well as those undergoing review for funding as of November 2024.

The Current State of Public Payer **Access** to CGTs in Canada

The following table provides a summary of the current public payer funding status of various CGTs across Canada. (Based on information in the public domain - may not be complete.)

Product	Indication(s)	Funding status
Cell Therapies		
Breyanzi® (lisocabtagene maraleucel)	<ul style="list-style-type: none"> Relapsed or refractory large B-cell lymphoma 	ON
Kymriah® (Tisagenlecleucel)	<ul style="list-style-type: none"> Pediatric acute lymphoblastic leukemia Diffuse large B-cell lymphoma 	AB, NS, ON, QC, SK
Tecartus® (Brexucabtagene autoleucel)	<ul style="list-style-type: none"> Relapsed or refractory mantle cell lymphoma Relapsed or refractory acute lymphoblastic leukemia 	ON, QC
Yescarta® (Axicabtagene ciloleucel)	<ul style="list-style-type: none"> Relapsed or refractory large B-cell lymphoma Relapsed or refractory follicular lymphoma 	AB, NS, ON, QC, SK ON
Gene Therapies		
Luxturna® (voretigene neparvovec)	<ul style="list-style-type: none"> Vision loss, inherited retinal dystrophy 	AB, ON, QC, SK
Zolgensma® (onasemnogene abeparvovec)	<ul style="list-style-type: none"> Spinal muscular atrophy, pediatrics 	BC, NB, NIHB, ON

The table below provides a summary of the health technology assessment (HTA) and pricing negotiation outcomes for CGT products that in various stages of the review process.

Product	Indication(s)	Status
Cell Therapies		
Breyanzi® (lisocabtagene maraleucel)	<ul style="list-style-type: none"> Relapsed or refractory large B-cell lymphoma 	<ul style="list-style-type: none"> Successful HTA Pricing and provincial funding TBD
Carvykti® (ciltacabtagene autoleucel)	<ul style="list-style-type: none"> Relapsed or refractory multiple myeloma (1-3L) 	<ul style="list-style-type: none"> Successful HTA Pricing and provincial funding TBD
Carvykti® (ciltacabtagene autoleucel)	<ul style="list-style-type: none"> Relapsed or refractory multiple myeloma (3L+) 	<ul style="list-style-type: none"> Successful HTA Pricing and provincial funding TBD
Kymriah® (Tisagenlecleucel)	<ul style="list-style-type: none"> Relapsed or refractory follicular lymphoma 	<ul style="list-style-type: none"> Successful HTA Pricing and provincial funding TBD
Yescarta® (Axicabtagene ciloleucel)	<ul style="list-style-type: none"> Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) 	<ul style="list-style-type: none"> Successful HTA and pricing Provincial funding TBD
Gene Therapies		
Beqvez® (fidanacogene elaparvovec)	<ul style="list-style-type: none"> Hemophilia B 	<ul style="list-style-type: none"> Successful HTA Pricing and provincial funding TBD
Casgevy® (exagamglogene autotemcel)	<ul style="list-style-type: none"> Transfusion-dependent beta-thalassemia 	<ul style="list-style-type: none"> Successful HTA Pricing and provincial funding TBD
Casgevy® (exagamglogene autotemcel)	<ul style="list-style-type: none"> Sickle-cell disease 	<ul style="list-style-type: none"> Successful HTA Pricing and provincial funding TBD
Hemgenix® (etranacogene dezaparvovec)	<ul style="list-style-type: none"> Hemophilia B 	<ul style="list-style-type: none"> Successful HTA Pricing and provincial funding TBD